Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM)

• Published in: Archives of Endocrinology and Metabolism 2015-12, Vol.59 (6), p.515-522
• Main Authors: Borges, Maria de Fátima, Franciscon, Priscila de Melo, Cambraia, Thamy Contursi, Oliveira, Débora Matias, Ferreira, Beatriz Pires, Resende, Elisabete Aparecida Mantovani Rodrigues de, Palhares, Heloísa Marcelina Cunha
• Format: Article
• Language: English
• Subjects: final stature; GnRH analogue; precocious central idiopathic puberty; precocious puberty; target stature
• ISSN: 2359-3997; 2359-4292; 2359-3997
• DOI: 10.1590/2359-3997000000101

Objective To report our experience of treating central precocious puberty (CPP) with a GnRH analogue with respect to the final heights (FH) attained in patients who completed treatment. Subjects and methods Among 105 records of children diagnosed with precocious puberty, 62 cases (54 girls and 8 boys), who were treated with leuprolide acetate/3.75 mg/monthly, were selected, and divided into 4 groups: group 1 (G1), 25 girls who attained FH; group 2 (G2), 18 girls who completed treatment but did not reach FH; group 3 (G3), 11 girls still under treatment; and group 4 (G4), 8 boys, 5 of which attained FH. Treatment was concluded at a bone age of 12 years, and follow-up continued until FH was achieved. Results In both G1 and G2 groups, height standard deviation score (SDS), weight-SDS and percentile of body mass index (PBMI) did not show intra/intergroup differences at the beginning and at interruption of treatment, but when added, G1+G2, height-SDS and weight-SDS differed significantly (p = 0.002 and 0.0001, respectively). In G1, 19 of 25 cases attained TH, and average height gain was 16.7 cm (7.7- 27.1); there was significant difference between FH and prediction of FH at the start (PFH at start) (p = 0.0001), as well as between PFH at interruption vs TH and vs FH (p = 0.007) with FH higher than TH (p = 0.004). Significant correlation was identified between FH and height gain after treatment. Conclusion As shown by some studies, GnRH analogue treatment was effective in children with CPP reaching FH near the genetic target.